Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Ever since Alois Alzheimer first described the neurological changes that characterize the disease that now bears his name, amyloid plaques have been a central focus of AD research. By the early ...

The study, “Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease ...

due to AD and mild AD dementia stages of the disease. These studies validate both the amyloid hypothesis and the therapeutic approach of Aβ plaque removal; and yet we know the story is much more ...

A University of Kansas study of rare gene mutations that cause hereditary Alzheimer's disease shows these mutations disrupt the production of a small sticky protein called amyloid. Plaques ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The neurodegenerative disorder affects millions of Americans, and its impact varies significantly across the country.

A study from Wake Forest University has found that drinking alcohol, even in moderate amounts, may speed up the progression ...